Suppr超能文献

自膨胀式可植入填充剂治疗粪便失禁的临床疗效和安全性:系统评价。

Clinical effectiveness and safety of self-expandable implantable bulking agents for faecal incontinence: a systematic review.

机构信息

HTA Austria - Austrian Institute for Health Technology Assessment GmbH, Garnisongasse 7/20, 1090, Vienna, Austria.

University of Vienna, Vienna, Austria.

出版信息

BMC Gastroenterol. 2022 Aug 17;22(1):389. doi: 10.1186/s12876-022-02441-4.

Abstract

PURPOSE

The purpose of this systematic review is to evaluate whether self-expandable implantable vs non-self-expandable injectable bulking agents (second-line therapies) are equal/superior in terms of effectiveness (severity, quality of life [QoL]) and safety (adverse events) for faecal incontinence (FI).

METHODS

A systematic review was conducted, and five databases were searched (Medline via Ovid, Embase, Cochrane Library, University of York Centre for Reviews and Dissemination, and International Network of Agencies for Health Technology database). In-/exclusion criteria were predefined according to the PICOS scheme. The Institute of Health Economics risk of bias (RoB) tool assessed studies' internal validity. According to the Grading of Recommendations, Assessment, Development and Evaluation approach, the strength of evidence for safety outcomes was rated. A qualitative synthesis of the evidence was used to analyse the data.

RESULTS

The evidence consists of eight prospective single-arm, before-after studies (166 patients) fulfilling the inclusion criteria for assessing clinical effectiveness and safety of implantable bulking agents. FI severity statistically significantly improved in five of seven studies rated by the Cleveland Clinic FI Score and in three of five studies measured by the Vaizey score. Statistically significant improved disease-related QoL was found in one of five studies measured by the FI QoL Score and in one of two studies rated by the American Medical Systems score. Procedure-related adverse events occurred in 16 of 166 patients (i.e., intraoperative complications, anal discomfort and pain). Device-related adverse events occurred in 48 of 166 patients, including prostheses' dislodgement and removed/extruded prostheses. Studies were judged with moderate/high RoB. The strength of evidence for safety was judged to be very low.

CONCLUSION

Implantable bulking agents might be an effective and safe minimally invasive option in FI treatment if conservative therapies fail. FI severity significantly improved, however, effects on QoL need to be explored in further studies. Due to the uncontrolled nature of the case series, comparative studies need to be awaited.

摘要

目的

本系统评价旨在评估自膨式可植入与非自膨式注射性填充剂(二线疗法)在疗效(严重程度、生活质量[QoL])和安全性(不良事件)方面对于粪便失禁(FI)是否等效/更优。

方法

进行了系统评价,并在五个数据库中进行了检索(通过 Ovid 进行的 Medline、Embase、Cochrane 图书馆、约克大学评价与传播中心、以及国际卫生技术机构数据库)。根据 PICOS 方案预先设定了纳入/排除标准。采用卫生经济研究所的偏倚(RoB)风险工具评估研究的内部有效性。根据推荐分级、评估、制定与评价方法,对安全性结局的证据强度进行了评级。使用定性综合分析来分析数据。

结果

证据包括八项满足评估可植入式填充剂的临床疗效和安全性的前瞻性单臂、前后对照研究(166 名患者)。在通过克利夫兰诊所 FI 评分评估的七项研究中的五项和通过 Vaizey 评分评估的五项研究中的三项中,FI 严重程度统计上显著改善。在通过 FI QoL 评分评估的五项研究中的一项和通过美国医学系统评分评估的两项研究中的一项中,发现与疾病相关的 QoL 有显著改善。在 166 名患者中的 16 名患者中发生了与手术相关的不良事件(即手术期并发症、肛门不适和疼痛)。在 166 名患者中的 48 名患者中发生了与器械相关的不良事件,包括假体移位和假体移除/脱出。研究的 RoB 被判定为中/高度。安全性的证据强度被判定为非常低。

结论

如果保守治疗失败,自膨式可植入填充剂可能是 FI 治疗的一种有效且安全的微创选择。FI 严重程度显著改善,但需要进一步研究来探索其对 QoL 的影响。由于病例系列的非控制性性质,需要等待比较研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/310b/9386976/08815c4f4e9f/12876_2022_2441_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验